Mandate

Vinge advises Epsilon’s owner Danir in connection with Epsilon’s merger with ÅF

October 18, 2012

Vinge is advising Danir, which is owned by Dan Olofsson, in connection with the merger of Danir’s subsidiary, Epsilon, with ÅF. The merger will be effected through ÅF acquiring all of the shares in Epsilon from Danir. The merger is driven by a strong industrial logic, since ÅF and Epsilon largely share a common culture and complement each other in terms of technical expertise, service offering, customer base and geographical presence. Over the last twelve months, the new ÅF Group would have had annual sales of approximately SEK 7.8 billion.

The consideration consists of an initial purchase price of approximately SEK 1,700 million (enterprise value), consisting partly of SEK 850 million in cash and partly of 5,985,915 newly issued class B shares in ÅF. There will also be an additional purchase price amounting to a maximum of SEK 1,100 million. The completion of the Transaction is conditional upon approval by the relevant competition authorities and approval by the ÅF Extraordinary General Meeting, which will be held on 19 November 2012.

Vinge’s team advising Danir consists of partners Peter Oscarsson, Jesper Ottergren and Pär Remmelid and associate Karolina Tjärnberg Jansson.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025